Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning session, 95 companies made new 52-week highs.
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 71 companies hit new 52-week highs.
Finally! An ETF for Bargain-Hunting Investors
Photo credit mohamed_hassan @ Pixabay
Have you ever been interested in trading stocks priced between $2 and $5 per share but were hesitant to buy given liquidity and volatility risks?
Now, you can easily own a basket of these low-priced names thanks to a new exchange-traded fund (ETF) from Direxion.
Stocks That Hit 52-Week Highs On Friday
During Friday's morning session, 137 companies made new 52-week highs.
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 119 companies set new 52-week highs.
Recap: Agenus Q2 Earnings
Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 32.14% over the past year to ($0.37), which missed the estimate of ($0.24).
Agenus Q2 EPS $(0.37) Misses $(0.24) Estimate, Sales $10.73M Miss $20.41M Estimate
Agenus (NASDAQ:AGEN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.24) by 54.17 percent. This is a 32.14 percent decrease over losses of $(0.28) per share from the same
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.